Drugs / FL118
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06206876 | Oct 2025 → Oct 2027 | pancreatic ductal adenocarcinoma | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FL118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06206876 ↗ |
| Modality | Small molecule | “FL118 is a small anti-tumor molecule” NCT06206876 ↗ |
| Route | Oral | “Patients receive FL118 orally (PO)” NCT06206876 ↗ |
| Target | DDX5 | “DDX5 degrader FL118” NCT06206876 ↗ |